Covalon to Showcase Clinical Innovation and Infection Prevention Leadership at Infusion Nurses Society 2026 Annual Meeting

Key Takeaways

• Covalon will present at INS 2026 in Louisville, KY
• Dr. Nancy Moureau will discuss gaps leading to CABSIs
• VALGuard line guard protects IV connections from gross contamination
• CovaClear dressings shield primary IV sites from fluids and microbes
• Hospitals increasingly adopt Covalon’s products to reduce infection risk

Pulse Analysis

Catheter‑associated bloodstream infections remain a costly and deadly challenge for healthcare systems, accounting for an estimated 30,000 deaths and billions of dollars in excess treatment expenses each year in the United States. As payers and regulators tighten reimbursement penalties for hospital‑acquired infections, clinicians are under pressure to adopt more robust prevention measures throughout the vascular access lifecycle. The INS annual meeting provides a pivotal forum where clinicians, researchers, and vendors converge to share the latest evidence and technologies aimed at closing the infection‑prevention gap.

Covalon is leveraging the conference to spotlight two flagship offerings: VALGuard Vascular Access Line Guard and CovaClear IV Cover dressings. VALGuard creates a physical barrier over IV line hubs, mitigating gross contamination from environmental exposure, while CovaClear adds an extra protective layer over primary dressings, reducing the need for frequent changes. Early adoption data from U.S. hospitals indicate a measurable decline in documented bloodstream infections when these products are integrated into standard care protocols, positioning Covalon as a fast‑growing player in the infection‑prevention market that is projected to exceed $5 billion globally by 2028.

The strategic exposure at INS 2026 could accelerate Covalon’s market penetration, especially as infection‑control committees seek validated, easy‑to‑implement solutions. By aligning its product narrative with clinical education—exemplified by Dr. Moureau’s session on the "gross gap" in protection—Covalon reinforces its credibility and differentiates itself from generic catheter accessories. Hospitals that adopt these technologies can anticipate lower infection‑related costs, improved quality metrics, and stronger compliance with emerging regulatory standards, ultimately driving sustainable revenue growth for Covalon and enhancing patient safety across care settings.